Payment overview · 2025
General Payments
$1,005.30
43 reported records · 14 companies
Healthcare provider profile · identity verified
Olusegun Ogunfowora, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FAR ROCKAWAY, NY · NPI 1275602963
Verified facts
What the public records show
CMS Open Payments records show Olusegun Ogunfowora, MD received $1,005.30 in general payments during 2025 across 43 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 25.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Rexulti, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1213 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $258.94 | 25.8% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $218.74 | 21.8% | 10 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $120.42 | 12.0% | 5 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $108.53 | 10.8% | 4 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $63.00 | 6.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.05 | 3.9% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $30.67 | 3.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.48 | 2.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.46 | 2.9% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $23.76 | 2.4% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $22.09 | 2.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.41 | 2.1% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.59 | 2.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.16 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,005.30 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $339.16 | 15 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $258.94 | 11 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $108.53 | 4 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $44.90 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $39.05 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $30.67 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.48 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.48 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.48 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.46 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $18.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 67 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 51 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
134 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
51 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
88 | 17 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
51 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
67 | 67 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1213 | 198 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2110 | 459 |
| Amlodipine Besylate | Amlodipine Besylate | 1603 | 356 |
| Furosemide | Furosemide | 1299 | 209 |
| Eliquis | Apixaban | 1213 | 198 |
| Metformin Hcl | Metformin Hcl | 1200 | 187 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1161 | 160 |
| Metoprolol Succinate | Metoprolol Succinate | 1025 | 192 |
| Gabapentin | Gabapentin | 967 | 239 |
| Tamsulosin Hcl | Tamsulosin Hcl | 853 | 177 |
| Famotidine | Famotidine | 821 | 97 |
| Losartan Potassium | Losartan Potassium | 820 | 178 |
| Mirtazapine | Mirtazapine | 614 | 137 |
| Lisinopril | Lisinopril | 495 | 94 |
| Clopidogrel | Clopidogrel Bisulfate | 444 | 100 |
| Carvedilol | Carvedilol | 439 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 438 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 422 | 60 |
| Sertraline Hcl | Sertraline Hcl | 409 | 58 |
| Levetiracetam | Levetiracetam | 398 | 88 |
| Duloxetine Hcl | Duloxetine Hcl | 395 | 47 |
| Montelukast Sodium | Montelukast Sodium | 390 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 376 | 103 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 354 | 42 |
| Januvia | Sitagliptin Phosphate | 352 | 59 |
| Allopurinol | Allopurinol | 346 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 342 | 55 |
| Hydralazine Hcl | Hydralazine Hcl | 317 | 60 |
| Donepezil Hcl | Donepezil Hcl | 313 | 51 |
| Nifedipine Er | Nifedipine | 309 | 77 |
| Divalproex Sodium | Divalproex Sodium | 302 | 41 |
| Potassium Chloride | Potassium Chloride | 301 | 72 |
| Omeprazole | Omeprazole | 300 | 91 |
| Simvastatin | Simvastatin | 297 | 73 |
| Latanoprost | Latanoprost | 278 | 92 |
| Trazodone Hcl | Trazodone Hcl | 273 | 55 |
| Tramadol Hcl | Tramadol Hcl | 257 | 67 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 229 | 96 |
| Xarelto | Rivaroxaban | 227 | 48 |
| Entresto | Sacubitril/Valsartan | 219 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 216 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 208 | 58 |
| Valsartan | Valsartan | 205 | 20 |
| Memantine Hcl | Memantine Hcl | 203 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 202 | 38 |
| Tradjenta | Linagliptin | 201 | 11 |
| Bupropion Hcl | Bupropion Hcl | 198 | 13 |
| Finasteride | Finasteride | 197 | 46 |
| Sevelamer Carbonate | Sevelamer Carbonate | 197 | 56 |
| Pregabalin | Pregabalin | 189 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 185 | 67 |
| Baclofen | Baclofen | 181 | 50 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 178 | 47 |
| Lorazepam | Lorazepam | 175 | 50 |
| Labetalol Hcl | Labetalol Hcl | 174 | 47 |
| Prednisone | Prednisone | 165 | 54 |
| Alogliptin | Alogliptin Benzoate | 163 | 39 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 163 | 35 |
| Enalapril Maleate | Enalapril Maleate | 160 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 149 | 55 |
| Midodrine Hcl | Midodrine Hcl | 149 | 41 |
| Humalog Kwikpen U-100 | Insulin Lispro | 143 | 27 |
| Nystatin | Nystatin | 143 | 64 |
| Amiodarone Hcl | Amiodarone Hcl | 138 | 35 |
| Jardiance | Empagliflozin | 134 | 34 |
| Enulose | Lactulose | 132 | 69 |
| Farxiga | Dapagliflozin Propanediol | 132 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 132 | 18 |
| Myrbetriq | Mirabegron | 129 | 14 |
| Ezetimibe | Ezetimibe | 125 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 122 | 48 |
| Torsemide | Torsemide | 119 | 28 |
| Spironolactone | Spironolactone | 118 | 47 |
| Albuterol Sulfate | Albuterol Sulfate | 116 | 38 |
| Alendronate Sodium | Alendronate Sodium | 114 | 39 |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 109 | 53 |
| Oxycodone Hcl | Oxycodone Hcl | 108 | 48 |
| Lacosamide | Lacosamide | 105 | suppressed |
| Folic Acid | Folic Acid | 104 | 16 |
| Lactulose | Lactulose | 104 | 41 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 103 | 56 |
| Santyl | Collagenase Clostridium Hist. | 100 | 36 |
| Silver Sulfadiazine | Silver Sulfadiazine | 96 | 42 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 95 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 94 | 21 |
| Meloxicam | Meloxicam | 92 | 36 |
| Doxycycline Hyclate | Doxycycline Hyclate | 91 | 50 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 91 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 90 | 25 |
| Ozempic | Semaglutide | 88 | 17 |
| Lokelma | Sodium Zirconium Cyclosilicate | 85 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 26 |
| Risperidone | Risperidone | 85 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 82 | suppressed |
| Ibuprofen | Ibuprofen | 80 | 37 |
| Clonazepam | Clonazepam | 79 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 77 | 19 |
| Olanzapine | Olanzapine | 73 | 18 |
| Topiramate | Topiramate | 73 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 22 |
| Atenolol | Atenolol | 72 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 71 | 46 |
| Ceftriaxone | Ceftriaxone Sodium | 70 | 51 |
| Azithromycin | Azithromycin | 69 | 45 |
| Novolog Flexpen | Insulin Aspart | 69 | 20 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 68 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 67 | 67 |
| Gemtesa | Vibegron | 67 | suppressed |
| Hydrocortisone | Hydrocortisone | 67 | 27 |
| Warfarin Sodium | Warfarin Sodium | 67 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 66 | 11 |
| Alprazolam | Alprazolam | 63 | 15 |
| Ammonium Lactate | Ammonium Lactate | 63 | 35 |
| Mupirocin | Mupirocin | 63 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 14 |
| Aripiprazole | Aripiprazole | 62 | suppressed |
| Levofloxacin | Levofloxacin | 62 | 38 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 26 |
| Vancomycin Hcl | Vancomycin Hcl | 61 | 37 |
| Brilinta | Ticagrelor | 60 | suppressed |
| Humalog | Insulin Lispro | 60 | 16 |
| Sodium Chloride | 0.9 % Sodium Chloride | 59 | 37 |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 56 | 32 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 32 |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 55 | 38 |
| Ipratropium Bromide | Ipratropium Bromide | 53 | 11 |
| Oxcarbazepine | Oxcarbazepine | 53 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 51 | suppressed |
| Rexulti | Brexpiprazole | 51 | 13 |
| Anastrozole | Anastrozole | 50 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 50 | suppressed |
| Colchicine | Colchicine | 50 | 16 |
| Nyamyc | Nystatin | 50 | 30 |
| Breo Ellipta | Fluticasone/Vilanterol | 49 | 15 |
| Budesonide | Budesonide | 49 | 22 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 48 | 29 |
| Ketoconazole | Ketoconazole | 48 | 26 |
| Naproxen | Naproxen | 48 | 30 |
| Galantamine Hbr | Galantamine Hbr | 47 | suppressed |
| Glipizide | Glipizide | 47 | 20 |
| Timolol Maleate | Timolol Maleate | 47 | 16 |
| Trulicity | Dulaglutide | 47 | 12 |
| Fluconazole | Fluconazole | 46 | 17 |
| Meclizine Hcl | Meclizine Hcl | 46 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 21 |
| Glipizide Er | Glipizide | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | 15 |
| Cephalexin | Cephalexin | 44 | 30 |
| Loperamide | Loperamide Hcl | 44 | 32 |
| Methimazole | Methimazole | 44 | 13 |
| Amantadine | Amantadine Hcl | 43 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 43 | 28 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 43 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 42 | 24 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 42 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | 11 |
| Amoxicillin | Amoxicillin | 41 | 34 |
| Bicalutamide | Bicalutamide | 41 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 41 | 12 |
| Mesalamine | Mesalamine | 41 | suppressed |
| Silodosin | Silodosin | 41 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 40 | 34 |
| Symbicort | Budesonide/Formoterol Fumarate | 40 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 17 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 39 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 29 |
| Glimepiride | Glimepiride | 38 | 11 |
| Combigan | Brimonidine Tartrate/Timolol | 37 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 37 | 15 |
| Bumetanide | Bumetanide | 36 | 14 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 36 | 19 |
| Lamotrigine | Lamotrigine | 35 | 11 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 34 | suppressed |
| Admelog Solostar | Insulin Lispro | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 16 |
| Creon | Lipase/Protease/Amylase | 33 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 33 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 31 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 31 | 20 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 31 | 14 |
| Metronidazole | Metronidazole | 31 | 16 |
| Rivastigmine | Rivastigmine | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Dutasteride | Dutasteride | 30 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 30 | 14 |
| Levofloxacin-D5w | Levofloxacin In Dextrose 5 % | 30 | 15 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 30 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 30 | 17 |
| Arnuity Ellipta | Fluticasone Furoate | 29 | suppressed |
| Calcium Acetate | Calcium Acetate | 29 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 29 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 27 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | suppressed |
| Lidocaine | Lidocaine | 27 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 27 | suppressed |
| Methotrexate | Methotrexate Sodium | 27 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Hydroxyurea | Hydroxyurea | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | 16 |
| Sucralfate | Sucralfate | 25 | 11 |
| Tramadol Hcl Er | Tramadol Hcl | 25 | suppressed |
| Clonidine | Clonidine | 24 | 11 |
| Linzess | Linaclotide | 24 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 24 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 23 | 12 |
| Digoxin | Digoxin | 23 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 23 | suppressed |
| Repaglinide | Repaglinide | 23 | suppressed |
| Brinzolamide | Brinzolamide | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Insulin Lispro | Insulin Lispro | 22 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 21 | 11 |
| Fentanyl | Fentanyl | 21 | suppressed |
| Haloperidol | Haloperidol | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 18 |
| Pradaxa | Dabigatran Etexilate Mesylate | 21 | 11 |
| Procrit | Epoetin Alfa | 21 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 21 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Verapamil Sr | Verapamil Hcl | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | 12 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 20 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 20 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Entacapone | Entacapone | 20 | suppressed |
| Phenobarbital | Phenobarbital | 20 | suppressed |
| Scopolamine | Scopolamine | 20 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 19 | 15 |
| Acetic Acid | Acetic Acid | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | 11 |
| Oxycontin | Oxycodone Hcl | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Midazolam Hcl | Midazolam Hcl | 17 | suppressed |
| Zonisamide | Zonisamide | 17 | suppressed |
| Clozapine | Clozapine | 16 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 16 | 15 |
| Cefepime Hcl | Cefepime Hcl | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 11 |
| Ssd | Silver Sulfadiazine | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 14 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | 11 |
| Kapspargo Sprinkle | Metoprolol Succinate | 14 | suppressed |
| Multaq | Dronedarone Hcl | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Valproic Acid | Valproic Acid | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Meropenem | Meropenem | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Fycompa | Perampanel | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,005.30 · 43 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABRYSVO, ACCRUFER, AMVUTTRA, CABENUVA, CAPLYTA, COMIRNATY, DOVATO, KISUNLA, Kerendia, NUPLAZID, OPSUMIT, PREVNAR 20, REXULTI, Rybelsus, TRELEGY ELLIPTA, UPTRAVI, WATCHMAN FLX | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error